HACD2 and Hepatic steatosis: A recent study in Hacd2LKO mice has revealed ameliorated obesity, hepatic steatosis, and diabetes in HFD-treated mice, which were achieved by upregulating thermogenic genes to enhance energy expenditure, positioning Hacd2 as a therapeutic target [3].